198 related articles for article (PubMed ID: 27742793)
21. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
He W; Liu J; Binkowitz B; Quan H
Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
[TBL] [Abstract][Full Text] [Related]
22. R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials.
Guo W; Ji Y; Li D
J Biopharm Stat; 2019; 29(3):411-424. PubMed ID: 30744484
[TBL] [Abstract][Full Text] [Related]
23. Two-stage dose finding for cytostatic agents in phase I oncology trials.
Yin G; Zheng S; Xu J
Stat Med; 2013 Feb; 32(4):644-60. PubMed ID: 22855354
[TBL] [Abstract][Full Text] [Related]
24. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
Kakurai Y; Hirakawa A; Hamada C
J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
[TBL] [Abstract][Full Text] [Related]
25. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
26. From CARs to TRUCKs and Beyond: Safely en Route to Adoptive T-cell Therapy for Cancer.
Dummy
EBioMedicine; 2016 Dec; 14():1-2. PubMed ID: 27986279
[No Abstract] [Full Text] [Related]
27. Bayesian optimal interval design for dose finding in drug-combination trials.
Lin R; Yin G
Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
[TBL] [Abstract][Full Text] [Related]
28. An adaptive dose-finding method using a change-point model for molecularly targeted agents in phase I trials.
Sato H; Hirakawa A; Hamada C
Stat Med; 2016 Oct; 35(23):4093-109. PubMed ID: 27221807
[TBL] [Abstract][Full Text] [Related]
29. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
Paoletti X; Kramar A
Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
[TBL] [Abstract][Full Text] [Related]
30. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
31. A dose-finding approach for genomic patterns in phase I trials.
Kaneko S; Hirakawa A; Kakurai Y; Hamada C
J Biopharm Stat; 2020 Sep; 30(5):834-853. PubMed ID: 32310707
[TBL] [Abstract][Full Text] [Related]
32. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
33. Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.
Bagley EM; Wages NA
J Biopharm Stat; 2024 Mar; 34(2):151-163. PubMed ID: 36879525
[TBL] [Abstract][Full Text] [Related]
34. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
Xie F; Ji Y; Tremmel L
Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
[TBL] [Abstract][Full Text] [Related]
35. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
Chen Z; Krailo MD; Sun J; Azen SP;
Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
[TBL] [Abstract][Full Text] [Related]
36. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
37. On the relative efficiency of model-assisted designs: a conditional approach.
Lin R; Yuan Y
J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
[TBL] [Abstract][Full Text] [Related]
38. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
39. Adaptive dose insertion in early phase clinical trials.
Hu B; Bekele BN; Ji Y
Clin Trials; 2013 Apr; 10(2):216-24. PubMed ID: 20819841
[TBL] [Abstract][Full Text] [Related]
40. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
